Statistical models for predicting response to interferon-alpha and spontaneous seroconversion in children with

Related Experiment Video

Updated: Sep 4, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

L Comanor1, J Minor, H S Conjeevaram

  • 1Bayer Diagnostics (formerly Chiron Diagnostics), Emeryville, CA 94301, USA.

Journal of Viral Hepatitis
|April 12, 2000
PubMed

Insights

New models predict which children with chronic hepatitis B will respond to interferon-alpha (IFN-alpha) therapy or achieve spontaneous seroconversion, aiding treatment decisions for pediatric HBV patients.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Medicine

Background:

  • Chronic hepatitis B (CHB) affects children worldwide.
  • Predicting treatment response and spontaneous seroconversion in pediatric CHB is challenging.
  • Accurate prognostic models are needed to guide therapy decisions.

Purpose of the Study:

  • To develop and validate prognostic models for predicting outcomes in children with CHB.
  • Identify children likely to respond to interferon-alpha (IFN-alpha) therapy.
  • Identify children likely to achieve spontaneous seroconversion.

Main Methods:

  • Utilized data from a multinational controlled trial of 70 children treated with IFN-alpha and 74 untreated children.
  • Employed SMILES (similarity of least squares) network analysis for multidimensional data integration.
  • Incorporated clinical data including age, gender, liver enzymes (AST, ALT), HBV DNA levels, IFN-alpha dose, pretreatment trends, liver biopsy, race, and transmission mode.

Main Results:

  • SMILES models achieved high prospective prediction accuracy: 89% for IFN-alpha responders, 96% for non-responders, 100% for seroconverters, and 93% for non-seroconverters.
  • Key predictors for IFN-alpha response included HBV DNA pretreatment direction, baseline HBV DNA, IFN-alpha dose, and gender.
  • Key predictors for spontaneous seroconversion included ALT pretreatment direction, baseline HBV DNA, age, and AST pretreatment direction.

Conclusions:

  • Prognostic models using SMILES demonstrate significant potential for predicting IFN-alpha response and spontaneous seroconversion in children with CHB.
  • These models can assist clinicians in determining the likelihood of treatment success or natural viral clearance.
  • Personalized treatment strategies for pediatric hepatitis B can be enhanced through these predictive tools.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...